CompletedNCT00094549
Olanzapine or divalproex for mild to moderate mania in bipolarity
About this title
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
Read the official source — NCT00094549Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Scottsdale and 41 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 500
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Lithuania, Romania, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00094549
- Official title
Show the full official title
Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale, United States · Beverly Hills, United States · Costa Mesa, United States
40 more locations
- Escondido, United States
- Orange, United States
- Pico Rivera, United States
- San Diego, United States
- Washington D.C., United States
- Boyton Beach, United States
- DeLand, United States
- North Miami, United States
- Tampa, United States
- Decatur, United States
- Marietta, United States
- Eagle, United States
- Chicago, United States
- Joliet, United States
- Wichita, United States
- Baltimore, United States
- Brooklyn, United States
- Buffalo, United States
- Rochester, United States
- Oklahoma City, United States
- Media, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Charlottesville, United States
- Virginia Beach, United States
- Bellevue, United States
- Charleston, United States
- Klaipėda, Lithuania
- Šiauliai, Lithuania
- Vilnius, Lithuania
- Ziegzdriu K, Lithuania
- Caguas, Puerto Rico
- Ponce, Puerto Rico
- Bucharest, Romania
- Târgu Mureş, Romania
- Lipetsk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including olanzapine, divalproex sodium and placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
